ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
公司代碼NDRA
公司名稱ENDRA Life Sciences Inc
上市日期Jun 28, 2017
CEOTokman (Alexander Y)
員工數量21
證券類型Ordinary Share
年結日Jun 28
公司地址3600 Green Ct Ste 350
城市ANN ARBOR
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編48105
電話17343350468
網址https://www.endrainc.com/
公司代碼NDRA
上市日期Jun 28, 2017
CEOTokman (Alexander Y)